Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
14
04
2021
accepted:
23
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
1
12
2021
Statut:
epublish
Résumé
Clinical outcomes are inferior for individuals with HIV having suboptimal CD4 T-cell recovery during antiretroviral therapy (ART). We investigated if the levels of infection and the response to homeostatic cytokines of CD4 T-cell subsets contributed to divergent CD4 T-cell recovery and HIV reservoir during ART by studying virologically-suppressed immunologic responders (IR, achieving a CD4 cell count >500 cells/μL on or before two years after ART initiation), and virologically-suppressed suboptimal responders (ISR, did not achieve a CD4 cell count >500 cells/μL in the first two years after ART initiation). Compared to IR, ISR demonstrated higher levels of HIV-DNA in naïve, central (CM), transitional (TM), and effector (EM) memory CD4 T-cells in blood, both pre- and on-ART, and specifically in CM CD4 T-cells in LN on-ART. Furthermore, ISR had higher pre-ART plasma levels of IL-7 and IL-15, cytokines regulating T-cell homeostasis. Notably, pre-ART PD-1 and TIGIT expression levels were higher in blood CM and TM CD4 T-cells for ISR; this was associated with a significantly lower fold-changes in HIV-DNA levels between pre- and on-ART time points exclusively on CM and TM T-cell subsets, but not naïve or EM T-cells. Finally, the frequency of CM CD4 T-cells expressing PD-1 or TIGIT pre-ART as well as plasma levels of IL-7 and IL-15 predicted HIV-DNA content on-ART. Our results establish the association between infection, T-cell homeostasis, and expression of PD-1 and TIGIT in long-lived CD4 T-cell subsets prior to ART with CD4 T-cell recovery and HIV persistence on-ART.
Identifiants
pubmed: 34449812
doi: 10.1371/journal.ppat.1009825
pii: PPATHOGENS-D-21-00814
pmc: PMC8397407
doi:
Substances chimiques
Anti-Retroviral Agents
0
Cytokines
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009825Subventions
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128837
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI110334
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: V.C.M. has received investigator initiated research grants (to the institution, unrelated to current work) from Bayer, Gilead Sciences, Lilly and ViiV. All other authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2019 Nov 13;69(11):1919-1925
pubmed: 30753360
Nat Rev Immunol. 2014 Jan;14(1):24-35
pubmed: 24336101
Clin Infect Dis. 2009 Feb 1;48(3):350-61
pubmed: 19123865
Immunol Invest. 2012;41(1):1-14
pubmed: 21563924
J Infect Dis. 2011 Oct 15;204(8):1217-26
pubmed: 21917895
J Virol. 2004 Feb;78(3):1160-8
pubmed: 14722271
Diabetes Care. 2010 Oct;33(10):2244-9
pubmed: 20664016
PLoS One. 2020 Jan 6;15(1):e0227124
pubmed: 31905222
Clin Infect Dis. 2009 Feb 1;48(3):328-37
pubmed: 19123868
J Infect Dis. 2013 Jul 15;208(2):249-59
pubmed: 23559466
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Science. 2012 Mar 9;335(6073):1188-93
pubmed: 22403383
PLoS Pathog. 2017 Nov 2;13(11):e1006624
pubmed: 29095912
J Infect Dis. 2011 Feb 1;203(3):364-71
pubmed: 21208929
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
Clin Infect Dis. 2005 Aug 1;41(3):361-72
pubmed: 16007534
Nat Med. 2016 Jul;22(7):754-61
pubmed: 27239760
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34
pubmed: 16810109
J Exp Med. 2006 Jun 12;203(6):1533-41
pubmed: 16735692
J Virol. 2019 Nov 26;93(24):
pubmed: 31578289
Chest. 2014 Dec;146(6):1543-1553
pubmed: 25080158
J Clin Invest. 2020 Jun 1;130(6):2872-2887
pubmed: 32436864
AIDS. 2006 Aug 22;20(13):1727-36
pubmed: 16931937
Immunity. 2008 Dec 19;29(6):848-62
pubmed: 19100699
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Front Immunol. 2021 Mar 25;12:638010
pubmed: 33868264
AIDS. 2010 Jul 31;24(12):1877-86
pubmed: 20588170
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Blood. 2013 May 23;121(21):4321-9
pubmed: 23589672
J Exp Med. 2007 Sep 3;204(9):2171-85
pubmed: 17724130
PLoS Pathog. 2016 Jul 14;12(7):e1005761
pubmed: 27415008
AIDS. 2013 Jun 1;27(9):1387-95
pubmed: 23435298
J Clin Invest. 2016 Jul 1;126(7):2745-56
pubmed: 27322062
J Immunol. 2007 Aug 1;179(3):1979-87
pubmed: 17641065
AIDS. 2012 Feb 20;26(4):465-74
pubmed: 22112603
BMC Infect Dis. 2011 Feb 08;11:43
pubmed: 21299909
AIDS. 2008 Apr 23;22(7):841-8
pubmed: 18427202
Blood. 2007 Jun 1;109(11):4671-8
pubmed: 17272504
JCI Insight. 2020 Oct 15;5(20):
pubmed: 33055422
J Virol. 2020 Jan 17;94(3):
pubmed: 31723024
Annu Rev Med. 2011;62:141-55
pubmed: 21090961
AIDS. 2013 Mar 27;27(6):973-979
pubmed: 23698063
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
Immunity. 2017 Oct 17;47(4):776-788.e5
pubmed: 29045906
J Acquir Immune Defic Syndr. 2010 Nov;55(3):316-22
pubmed: 20581689
Nat Med. 2011 Jun 26;17(7):830-6
pubmed: 21706028
Expert Rev Anti Infect Ther. 2016;14(1):29-40
pubmed: 26513236
HIV Med. 2015 Nov;16(10):591-8
pubmed: 25990642
AIDS Res Ther. 2011 Jan 18;8(1):2
pubmed: 21244701
J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):387-95
pubmed: 21546844
Clin Infect Dis. 2013 Jul;57(2):314-21
pubmed: 23575194
AIDS. 2006 Feb 14;20(3):371-7
pubmed: 16439870
Clin Infect Dis. 2010 May 1;50(9):1300-8
pubmed: 20367229
J Virus Erad. 2016 Jul 01;2(3):183-6
pubmed: 27482460
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
AIDS. 2013 Mar 13;27(5):769-79
pubmed: 23719349
Clin Infect Dis. 2014 May;58(9):1312-21
pubmed: 24457342
J Virol. 2010 Jul;84(13):6505-14
pubmed: 20410277
Exp Mol Med. 2019 Dec 11;51(12):1-9
pubmed: 31827070
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):456-62
pubmed: 24220289
HIV Med. 2009 Nov;10(10):657-60
pubmed: 19601997
PLoS Pathog. 2016 Jan 07;12(1):e1005349
pubmed: 26741490
Antiviral Res. 2015 May;117:69-74
pubmed: 25766861
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):541-6
pubmed: 18645520
Science. 2006 Jun 9;312(5779):1530-3
pubmed: 16763152
Blood. 2009 Jun 18;113(25):6304-14
pubmed: 19380868
Curr HIV/AIDS Rep. 2012 Mar;9(1):81-90
pubmed: 22198819
J Infect Dis. 2009 Jun 15;199(12):1872-82
pubmed: 19432535
Clin Infect Dis. 2014 Nov 1;59(9):1312-21
pubmed: 25073894
J Infect Dis. 2017 Mar 15;215(6):911-919
pubmed: 28453847
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):118-24
pubmed: 20980914
AIDS. 2013 Jun 1;27(9):1433-41
pubmed: 23945504
PLoS Pathog. 2017 Apr 20;13(4):e1006285
pubmed: 28426825
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8
pubmed: 18285713
Nat Commun. 2015 Oct 09;6:8495
pubmed: 26449164
J Acquir Immune Defic Syndr. 2010 May 1;54(1):59-62
pubmed: 20182359
AIDS. 2013 Mar 27;27(6):1021-1026
pubmed: 23196936
J Int AIDS Soc. 2015 Jun 29;18:20052
pubmed: 26130226
Retrovirology. 2017 Jan 13;14(1):2
pubmed: 28086908
J Infect Dis. 2005 Feb 1;191(3):348-57
pubmed: 15633093
Clin Dev Immunol. 2012;2012:670957
pubmed: 22474480
J Virol. 2014 Nov;88(21):12385-96
pubmed: 25122785